396 related articles for article (PubMed ID: 19139295)
1. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
Giacomini PS; Arnold DL; Bar-Or A; Antel JP
Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
[No Abstract] [Full Text] [Related]
2. Use of interferon-beta in the treatment of multiple sclerosis.
Derwenskus J; Lublin FD
Adv Neurol; 2006; 98():257-71. PubMed ID: 16400838
[No Abstract] [Full Text] [Related]
3. Seeing injectable MS therapies differently: they are more similar than different.
Fox RJ; Arnold DL
Neurology; 2009 Jun; 72(23):1972-3. PubMed ID: 19439722
[No Abstract] [Full Text] [Related]
4. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
Banwell B; Tremlett H
Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
[No Abstract] [Full Text] [Related]
5. Definition of responder: introduction.
Comi G
Neurol Sci; 2008 Sep; 29 Suppl 2():S209-10. PubMed ID: 18690493
[TBL] [Abstract][Full Text] [Related]
6. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
Gout O
Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
[No Abstract] [Full Text] [Related]
7. The use of modern magnetic resonance techniques to monitor disease evolution in multiple sclerosis.
Filippi M; Rocca MA
Adv Neurol; 2006; 98():167-83. PubMed ID: 16400834
[No Abstract] [Full Text] [Related]
8. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study.
Chiu AW; Richert N; Ehrmantraut M; Ohayon J; Gupta S; Bomboi G; Gaindh D; Cantor FK; Frank JA; McFarland HF; Bagnato F
Arch Neurol; 2009 Jan; 66(1):39-43. PubMed ID: 19001157
[TBL] [Abstract][Full Text] [Related]
9. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.
Toprak MK; Cakir B; Ulu EM; Arat Z; Benli US; Can U; Ağildere M
Int J Neurosci; 2008 Dec; 118(12):1645-58. PubMed ID: 18937112
[TBL] [Abstract][Full Text] [Related]
10. Early treatment of multiple sclerosis to prevent neurologic damage.
Coyle PK
Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
[TBL] [Abstract][Full Text] [Related]
11. The use of MRI as an outcome measure in clinical trials.
Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
[TBL] [Abstract][Full Text] [Related]
12. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta.
McDonald WI; Miller DH; Thompson AJ
Ann Neurol; 1994 Jul; 36(1):14-8. PubMed ID: 8024255
[No Abstract] [Full Text] [Related]
13. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
14. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis.
Biernacki K; Antel JP; Blain M; Narayanan S; Arnold DL; Prat A
Arch Neurol; 2005 Apr; 62(4):563-8. PubMed ID: 15824253
[TBL] [Abstract][Full Text] [Related]
15. The role of MRS and fMRI in multiple sclerosis.
Tartaglia MC; Arnold DL
Adv Neurol; 2006; 98():185-202. PubMed ID: 16400835
[TBL] [Abstract][Full Text] [Related]
16. Interferon neutralizing antibodies in multiple sclerosis: a new perspective.
Phillips JT
Arch Neurol; 2010 Apr; 67(4):386-7. PubMed ID: 20385901
[No Abstract] [Full Text] [Related]
17. Is progressive multiple sclerosis a gray matter disease?
Geurts JJ
Ann Neurol; 2008 Sep; 64(3):230-2. PubMed ID: 18825672
[No Abstract] [Full Text] [Related]
18. Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy.
Falcone M; Scalise A; Minisci C; Romito D; Cancelli I; Gigli GL
Neurol Sci; 2006 Apr; 27(1):58-62. PubMed ID: 16688601
[TBL] [Abstract][Full Text] [Related]
19. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
20. The use of glatiramer acetate in the treatment of multiple sclerosis.
Wolinsky JS
Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
